Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
Wegovy pill: How does it compare to injections and what are the side effects?
Weight Loss: What I Wish I’d Known Before Taking Compounded Semaglutide
Semaglutide erased the constant mental chatter about food that had ruled her life, but along with it went her awareness of basic needs.
Writer Kristen Reed shares her weight loss journey with compounded semaglutide. Photography courtesy of Kristen Reed
Health and wellness touch everyone’s life differently. This is one person’s story. The views and opinions expressed are those of the speaker and do not necessarily reflect the views or positions of Healthline Media.
FDA Approves Wegovy Weight Loss Pill: How It Compares to Injectables
The Food and Drug Administration (FDA) recently approved a tablet version of the GLP-1 drug Wegovy for weight loss. Image courtesy of Novo Nordisk
Novo Nordisk officials said a new pill version of its weight loss drug Wegovy is now available in the United States.
The Food and Drug Administration recently approved the Wegovy tablet as a prescription treatment for obesity and weight management.
Stopping GLP-1s May Lead to Weight Regain In Less Than 2 Years, Review Finds
Research shows that people who stop taking GLP-1 medications regain weight within 2 years. Image Credit: Tatsiana Volkava/Getty Images
A new study has found that people regain weight within 2 years of stopping a GLP-1 drug.
Metabolic improvements also tend to fade within that time, researchers found.
Experts advise that slowly tapering off the medication is better than quitting abruptly.
Tirzepatide, Hormone Therapy May Aid Weight Loss After Menopause
A combination of hormone therapy and the GLP-1 drug tirzepatide may promote weight loss in postmenopausal females. Image Credit: Mauro Grigollo/Stocksy
A new study found that postmenopausal females who use hormone therapy in combination with tirzepatide experience greater weight loss compared to those who don’t.
Tirzepatide (Zepbound) is an FDA-approved medication prescribed for weight loss. It’s also the active ingredient in the GLP-1 medication Mounjaro to treat type 2 diabetes.
Oral Semaglutide Lowers Heart Failure Risk in People with Type 2 Diabetes
Emerging evidence suggests that oral semaglutide may reduce the risk of heart failure–related events in people with type 2 diabetes. JasonDoiy/Getty Images
Oral semaglutide may reduce heart failure events in high-risk individuals with type 2 diabetes.
The benefit appeared strongest among those with a common but hard-to-treat form of heart failure.
Type 2 diabetes and heart disease often co-occur and the findings could pave the way for new treatments.
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue Up 46% in Q4
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer’s monthly obesity shot.
Pfizer beat Novo in the ferocious battle to acquire …